<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41273">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569086</url>
  </required_header>
  <id_info>
    <org_study_id>PIP/TAZO-INTERMEDIATE</org_study_id>
    <nct_id>NCT02569086</nct_id>
  </id_info>
  <brief_title>Piperacillin PK Analysis in Severe Sepsis Patients</brief_title>
  <official_title>Population Pharmacokinetics of Piperacillin in the Early Phase of Severe Sepsis - Does Standard Dosing Result in Therapeutic Plasma Concentrations?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibiotic dosing in severe septic patients poses a challenge for clinicians due to the
      pharmacokinetic changes seen in this population. Piperacillin/tazobactam is often used for
      empirical treatment, and initial appropriate dosing is crucial for reducing mortality.

      The investigators aim is to determined the pharmacokinetic profile of piperacillin 4g every
      8 hour in 20 patients treated empirically for severe sepsis. A PK population model will be
      established with the dual purpose to assess current standard treatment and to simulate
      alternative dosing regimens and modes of administration. Time above the minimal inhibitory
      concentration (T&gt;MIC) predicted for each patient will be evaluated against MIC for pathogens
      detected. Pharmacokinetic-pharmacodynamic (PK-PD) targets evaluated are 100% f T&gt;MIC and 50%
      fT&gt;4xMIC.

      Only patients who are prescribed piperacillin empirically by the treating physician are
      enrolled in the study. The investigators have no influence on the choice of treatment
      prescribed to the patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>100% f T&gt;MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval.</measure>
    <time_frame>Participants will be followed to day five (120 hours) after initiation of piperacillin/tazobactam treatment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>50% f T&gt;4xMIC: Free Piperacillin Concentration Maintained at a level four times above the MIC 50% of the Dosing Interval.</measure>
    <time_frame>Participants will be followed to day five (120 hours) after initiation of piperacillin/tazobactam treatment.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Sepsis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe sepsis treated empirically with Piperacillin/Tazobactam
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment with Piperacillin/Tazobactam 4g/0.5g every 8 hour for less than 48 hours

        Exclusion Criteria:

          -  renal replacement therapy

          -  Age under 18
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristina Öbrink-Hansen, MD</last_name>
    <phone>+45 26133705</phone>
    <email>krisoebr@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Merete Storgaard, MD, Ph.D</last_name>
    <email>merestor@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Infectious Diseases, Aarhus University Hospital, Denmark</name>
      <address>
        <city>Aarhus</city>
        <state>Danmark</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Öbrink-Hansen</last_name>
      <phone>+45 26133705</phone>
      <email>krisoebr@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 5, 2015</lastchanged_date>
  <firstreceived_date>September 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Kristina Öbrink-Hansen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Piperacillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
